Israel’s BrainStorm has received FDA approval to use its Nurown stem cells in a Phase 2 trial for the treatment of Multiple Sclerosis (MS). MS affects approximately 1 million individuals in the U.S. and 2.5 million individuals worldwide.  Nurown is … Continue reading →

A patient with amyotrophic lateral sclerosis (ALS) has testified to the effectiveness of the treatment developed by Israel’s Brainstorm Cell Therapeutics Ltd. http://www.globes.co.il/serveen/globes/docview.asp?did=1000670741&fid=1725